ImmunityBio Q2 net product revenue $50.7M, up 92% YoY; eighth consecutive quarter of growth

ImmunityBio, Inc.

Net product revenue $50.7M in Q2 2026, up 92% YoY and 15% sequentially; first-half revenue $94.8M, up 121% YoY.
Cash and marketable securities $357.4M as of June 30, 2026; adjusted net loss improved to $81.0M from $89.9M YoY.
FDA accepted sBLA for ANKTIVA plus BCG in BCG-unresponsive NMIBC with papillary disease; PDUFA Jan 6, 2027.
UAE granted broadest marketing authorization for ANKTIVA across BCG-unresponsive NMIBC and metastatic NSCLC.
Exclusive development and supply agreement with Japan BCG Laboratory for intravesical Tokyo-172 BCG in NMIBC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.